Western blot analysis of Phospho-p70 S6 Kinase pSer411 in Insulin-treated HeLa whole cell lysates with a blocking peptide (lane 1) and no blocking peptide (lane 2) using a Phospho-p70 S6 Kinase pSer411 polyclonal antibody (Product # PA5-35700).
|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide derived from human p70 S6 Kinase around the phosphorylation site of Serine 411|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.4, with 50% glycerol|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:500-1:2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Concentration is lot-specific and will vary from 0.5-0.6 mg/ml
Ribosomal S6 kinase has two isoforms, termed S6K1 (S6Ka) and S6K2 (S6Kb). The S6K1 isoform has two splicing forms, which are the products of alternative start codon usage. The first splicing form, p70S6K or p70S6K1, has a predicted molecular mass of 56 kDa and an apparent molecular mass (SDS-PAGE) of 70 kDa. The second isoform, p85S6K or p85S6K1, contains 23 extra amino acid residues at the N terminus, resulting from the alternative start codon. It has a predicted molecular mass of 59 kDa and an apparent molecular mass of 85 kDa. Both, p70 and p85 S6K1 are activated by multiple S/T phosphorylations in response to various mitogenic stimuli and nutrients. This is accompanied by significant mobility shift in the migration of both forms, when analyzed by SDS-PAGE electrophoresis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.